Who are Nimotuzumab ( h-R3)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nimotuzumab Injection, RT plus Nimotuzumab, Cetuximab injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nimotuzumab-h-r3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nimotuzumab ( h-R3) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nimotuzumab ( h-R3) (Nimotuzumab ( h-R3)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR inhibitor monoclonal antibody. Area: Oncology.

phase 3 EGFR inhibitor monoclonal antibody EGFR (Epidermal Growth Factor Receptor) Oncology Biologic Live · refreshed every 30 min

Target snapshot

Nimotuzumab ( h-R3) (Nimotuzumab ( h-R3)) — El Kendi Pharmaceuticals Manufacturing Company. Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nimotuzumab ( h-R3) TARGET	Nimotuzumab ( h-R3)	El Kendi Pharmaceuticals Manufacturing Company	phase 3	EGFR inhibitor monoclonal antibody	EGFR (Epidermal Growth Factor Receptor)
Nimotuzumab Injection	Nimotuzumab Injection	Biotech Pharmaceutical Co., Ltd.	marketed	EGFR inhibitor monoclonal antibody	EGFR (Epidermal Growth Factor Receptor)
RT plus Nimotuzumab	RT plus Nimotuzumab	Sun Yat-sen University	phase 3	EGFR inhibitor monoclonal antibody	EGFR (Epidermal Growth Factor Receptor)
Cetuximab injection	Cetuximab injection	Shanghai Miracogen Inc.	phase 3	EGFR inhibitor monoclonal antibody	EGFR (Epidermal Growth Factor Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR inhibitor monoclonal antibody class)

Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
El Kendi Pharmaceuticals Manufacturing Company · 1 drug in this class
Shanghai Miracogen Inc. · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nimotuzumab ( h-R3) — Competitive Intelligence Brief. https://druglandscape.com/ci/nimotuzumab-h-r3. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab